Poly Medicure is a global medical device manufacturer that historically built its franchise on infusion therapy, where it holds an 11% global market share with 600 million IV catheters sold annually. The business is deliberately shifting its revenue mix away from that mature base: infusion therapy fell from 57% of revenue in Q4 FY25 to 50% in Q4 FY26, while renal, cardiology, critical care, and the newly acquired orthopedics and catheter businesses now contribute over 50%. Standalone gross margin expanded 128 basis points to 68.1% in FY26, and the company guides standalone EBITDA margin of 25-27% for FY27, a level that reflects pricing power and manufacturing efficiency. The competitive structure is favorable in its chosen niches: in renal, Poly Medicure is the only domestic player facing Chinese competition, and in critical care only two or three players operate globally. This is not a commodity scale game; it is a portfolio of specialized, regulated devices where the company's 399 patents and 15-20 year customer relationships underpin its position.
The persistence of these economics rests on barriers that are difficult and slow to replicate. Regulatory approvals are the first gate: EU MDR certifications, FDA clearances, and DCGI approvals take years, and the company just received 15 EU MDR approvals in the last quarter with 15 more expected within six months. Customer stickiness is evidenced by the fact that Poly Medicure has hardly lost any large customer in 15-20 years, a result of quality, performance, and innovation. In India, the import substitution opportunity is structural, as 70% of the medical device industry is import-driven, and the company is working with the government on anti-dumping measures against Chinese renal products. The newly acquired PendraCare and Citieffe facilities operate at only 50-60% capacity, providing a clear path to margin improvement as volumes scale and cross-selling begins. These are not transient advantages; they are embedded in qualification cycles, switching costs, and a domestic manufacturing base that takes years to replicate.
The inflection point is now, driven by the full-year consolidation of PendraCare and Citieffe, which together generated EUR25.5 million in calendar 2025 and are expected to improve from mid-teens EBITDA margins to 18-20% over two to three years. For FY27, management guides consolidated revenue of INR2,300-2,400 crore, up from INR1,875 crore in FY26, with standalone revenue of INR1,900-1,950 crore. Domestic standalone growth is guided above 20% and international above 15%, supported by the Brazil acquisition of Medyneo for $40,000, which secures ANVISA and import licenses and saves 18-24 months of regulatory time. By mid-2028, 18-24 months from now, the business should be operating with over 1,000 installed dialysis machines (450 placed in FY26, with a pipeline of 600 bids), a completed 2,000-patient cardiology registry (650 enrolled so far), and commercialized IVL and drug-eluting balloons, which are currently 90% imported and where Poly Medicure will be the first domestic manufacturer. The revenue mix will continue shifting toward higher-technology segments, with the long-term target of one-third India and two-thirds rest of world already in motion.
Management's walk-talk record is mixed but improving. In November 2025, they cut FY26 revenue growth guidance from 20% to 15-16% due to international headwinds, yet they maintained the 25-27% EBITDA margin guidance and delivered on it (H1 26.7%, Q3 26.8% standalone). They also lowered renal sales guidance from INR220-250 crore to about INR200 crore and trimmed dialysis machine placements from 500-600 to 450, but they delivered on capex of INR250 crore for FY26 and on new product launches (35 group-level in FY26). In May 2026, they provided explicit FY27 guidance for revenue, margins, and capex of INR200-225 crore, and they claim to have met every Q3 commitment, including H2 revenue 20% above H1 and the 450 machine placements. Capital allocation remains disciplined: the company holds INR842 crore in cash, funded the acquisitions without significant dilution, and is investing in automation to offset raw material cost increases. The recent one-time regulatory provisions and lower-margin acquisitions pressured consolidated PAT, but this is operational noise, not a structural deterioration.
The quantified earnings path for FY27 is clear: standalone revenue of INR1,900-1,950 crore at 25-27% EBITDA margin implies standalone EBITDA of INR475-526 crore; consolidated revenue of INR2,300-2,400 crore at 23-25% implies consolidated EBITDA of INR529-600 crore. Beyond that, if the company sustains 15-20% growth and acquired companies improve to 18-20% EBITDA margins, consolidated revenue could reach INR2,700-2,900 crore by FY28 with margin expansion. The key falsifier is gross margin erosion: raw material costs are up about 20%, and management expects a 200-300 basis point decline from 68% to 66% unless crude softens, though they have achieved 3-5% price increases from customers. Working capital is also a watchpoint, with receivables days rising from 68 to 86 and inventory days from 50 to 58. The single most important test is whether the company can hold domestic growth above 20% and international above 15% while integrating acquisitions and defending margins against Chinese dumping and import duty inversions. If those numbers hold, the business will be a larger, more diversified, and higher-margin compounder; if not, the margin compression will be the first signal of trouble.
companyname: Poly Medicure Limited ticker: POLYMED sector: Medical Devices / MedTech - Disposable Medical Devices Poly Medicure (Polymed) is a New Delhi-based medical device manufacturer founded in 1995 by the Baid family. It designs, manufactures, and sells disposable and high-complexity medical devices across infusion therapy, vascular access, renal care, cardiology, critical care, and orthopedics. The company operates 12 manufacturing facilities across India, China, Egypt, and Italy (annual ...
Read the full report →capex, margin expansion, regulatory approval, geographic expansion
FY27 consolidated revenue guided at INR2,300-2,400 crores; stand-alone revenue guided at INR1,900-1,950 crores with domestic growth >20% and international growth >15% driven by domestic expansion and international market consolidation
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Poly Medicure Limited and 4,900+ companies.
5-day free pass. No card required.